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Airway epithelium restricts penetration of inhaled pathogens into the underlying 17 
tissue and plays a crucial role in innate immune defense against respiratory infections. 18 
The whooping cough agent, Bordetella pertussis, adheres to ciliated cells of human 19 
airway epithelium and subverts its defense functions through the action of secreted 20 
toxins and other virulence factors. We have examined the impact of B. pertussis 21 
infection and of adenylate cyclase toxin (CyaA) action on the functional integrity of air-22 
liquid interface (ALI)-cultured human bronchial epithelial cells. B. pertussis adhesion to 23 
the apical surface of polarized pseudostratified VA10 cell layers provoked disruption of 24 
tight junctions and caused drop of the trans-epithelial electrical resistance (TEER). The 25 
reduction of TEER depended on the capacity of the secreted CyaA toxin to elicit cAMP 26 
signaling in epithelial cells through its adenylyl cyclase enzyme activity. Both purified 27 
CyaA and cAMP signaling drugs triggered decrease of TEER of VA10 cell layers. Toxin-28 
produced cAMP signaling caused actin cytoskeleton rearrangement and induced mucin 29 
5AC production and IL-6 secretion, while inhibiting IL-17A-induced secretion of the IL-8 30 
chemokine and of the antimicrobial peptide beta defensin-2. These results indicate that 31 
CyaA toxin activity compromises the barrier and innate immune functions of Bordetella-32 
infected airway epithelia.  33 
 34 
KEYWORDS: B. pertussis, airway epithelia, CyaA, tight junctions, antimicrobial 35 
peptides, immunomodulatory cytokines 36 
  37 
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INTRODUCTION  38 
 Despite availability and world-wide use of pertussis vaccines, whooping cough 39 
(pertussis) remains the least controlled vaccine-preventable infectious disease. The 40 
illness is primarily caused by the Gram-negative coccobacillus Bordetella pertussis and 41 
about 10% of milder whooping cough cases are caused by the related organism B. 42 
parapertussishu. The agent is transmitted by aerosolized droplets (1, 2) and upon 43 
inhalation the bacteria bind to the ciliated epithelial cells along the airway. With 44 
progressing proliferation, B. pertussis can reach the bronchioles and lung alveoli. It was 45 
proposed that a large fraction of live bacteria recovered from infected mouse lungs may 46 
have been residing inside alveolar macrophages (3). B. pertussis was also repeatedly 47 
found to survive and proliferate inside human macrophages (4, 5) and within epithelial 48 
cells infected ex vivo (6, 7). Moreover, two month after an infant patient was diagnosed 49 
with whooping cough disease, persisting B. pertussis antigens could still be detected in 50 
its airway epithelial cells (8). However, it remains unclear whether intracellular survival 51 
of B. pertussis within host epithelial cells, or in alveolar macrophages, plays any role in 52 
the pathophysiology of whooping cough disease, which can last for up to three months. 53 
 B. pertussis produces a number of virulence factors that enable it to overcome 54 
the innate and adaptive immune defense functions of airway mucosa. Several types of 55 
adhesins produced in parallel (e.g. fimbriae, filamentous hemagglutinin (FHA), pertactin) 56 
appear to mediate adhesion of the bacteria to human ciliated epithelia or macrophage 57 
cells. B. pertussis further produces several complement resistance factors and at least 58 
two potent immunomodulatory toxins, the pertussis toxin (PTX) and the adenylate 59 
cyclase toxin-hemolysin (CyaA). These play a major role in subversion of host innate 60 
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and adaptive immune defense. The underexplored Type III Secretion System (T3SS) of 61 
Bordetellae then delivers immunomodulatory (BopN) and cytotoxic (BteA/BopC) 62 
effectors into host cells, but the mechanism by which the T3SS contributes to 63 
pathogenesis of B. pertussis infections remains unknown (2, 9, 10). 64 
 The adenylate cyclase toxin-hemolysin (ACT, AC-Hly or CyaA) plays a particular 65 
role in the initial phases of B. pertussis infection (11). CyaA belongs to the Repeats-in-66 
toxin (RTX) family of proteins and it consists of an N-terminal cell invasive adenylate 67 
cyclase enzyme domain (~384 residues) that is fused to a pore-forming RTX cytolysin 68 
(Hly) moiety (~1322 residues) (12, 13). Through binding to the CD11b subunit of the 69 
complement receptor 3 (αMβ2 integrin, CD11b/CD18, or Mac-1), the CyaA toxin primarily 70 
targets host myeloid phagocytes (14). It inserts into their cell membrane and upon 71 
forming a transmembrane conduit for influx of extracellular Ca2+ ions, CyaA delivers its 72 
N-terminal adenylate cyclase (AC) domain into the cytosol of cells (15). There the AC 73 
enzyme is activated by calmodulin and catalyzes massive and unregulated conversion 74 
of ATP into the second messenger molecule 3',5'-cyclic adenosine monophosphate 75 
(cAMP) (16). cAMP signaling then instantly ablates the bactericidal functions of the 76 
myeloid phagocytes, such as the oxidative burst and opsonophagocytic killing of 77 
bacteria by neutrophils and macrophages (16-20). In parallel, the Hly moiety 78 
oligomerizes into cation-selective pores and permeabilizes cells for efflux of cytosolic K+ 79 
ions, activating MAPK signaling (21).  80 
 With a reduced efficacy, CyaA can bind, penetrate and intoxicate by cAMP a 81 
variety of other host cell types that do not express CR3 (CD11b- cells), such as 82 
erythrocytes or epithelial cells (14, 22, 23). However, very little is known about how 83 
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CyaA action affects the function of airway epithelial linings. CyaA appears to translocate 84 
rather inefficiently through the apical membrane of polarized epithelial cells (24), but it 85 
could be delivered into epithelial cells by bacterial outer membrane vesicles (25). This 86 
raises the possibility that cAMP produced by OMV-delivered CyaA might compromise 87 
tight junction integrity and enable the free secreted toxin to access the basolateral side 88 
of the layer, from where it can rather efficiently invade epithelial cells (24). Moreover, B. 89 
pertussis bacteria were recently shown to secrete high amounts of CyaA in the 90 
presence of calcium and albumin, as present in human respiratory secretions (26-28). 91 
This indicates that intoxication of airway epithelial cells by CyaA-produced cAMP likely 92 
plays a more important role in the pathophysiology of B. pertussis infections than 93 
previously anticipated.  94 
 The airway epithelium represents the first line of innate immune defense against 95 
respiratory pathogens (29). The secreted mucins form a protective gel layer over the 96 
epithelial surface that traps inhaled particles and microorganisms, enabling their 97 
removal by the mucociliary escalator (29, 30). Expression of Toll-like receptors (e.g. 98 
TLR2 and TLR4) and of the endotoxin receptor CD14 enables the airway epithelial cells 99 
to sense the presence of components released by infecting bacteria, such as the LPS 100 
and lipoproteins/lipopeptides, triggering secretion of cytokines and antimicrobial 101 
peptides (31, 32). Cytokines secreted by the epithelia can then act as chemoattractants, 102 
as pro/anti-inflammatory regulators, or as maturation signals for intraepithelial immune 103 
cells (32, 33). Tight packing of the epithelial cells through tight junctions plays a key role 104 
in the barrier function of the epithelial layer, preventing penetration of inhaled particles 105 
and microbes into the underlying tissue (34).  106 
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 We have previously shown that when grown in air-liquid interface cultures (ALI), 107 
the human bronchial epithelial cell line VA10 can form a pseudo-stratified epithelium 108 
that forms functional tight junctions, secretes IL-8 and antimicrobial peptides, and 109 
responds to bacterial components (35-38). Here, we used this model to analyze the 110 
effects of B. pertussis CyaA toxin action on the barrier function and immune response of 111 
bronchial epithelium. We show that B. pertussis infection and especially the elevation of 112 
cAMP by CyaA toxin compromises tight junction integrity and enhances mucin 113 
production, while modulating cytokine and antimicrobial peptide secretion by polarized 114 
airway epithelial cells.  115 
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MATERIALS AND METHODS 116 
Reagents and antibodies. Bronchial/Tracheal epithelial cell growth medium 117 
(B/TEGM) was obtained from Cell applications, USA. Dulbecco’s Modified Eagles 118 
Medium: Nutrient mixture F-12 (DMEM/F12) was purchased from Thermo Fisher, USA. 119 
Serum substitute Ultroser G was obtained from PALL Life Sciences, USA. Antibody 120 
against zonula occludens-1 (ZO-1; polyclonal Rabbit), junctional adhesion molecule A 121 
(JAMA; polyclonal rabbit), claudin-1 (monoclonal mouse), claudin-4 (polyclonal rabbit) 122 
and Alexa Flour 488 conjugated anti-mouse IgG were purchased from Thermo 123 
Scientific, USA. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (polyclonal 124 
rabbit), E-cadherin (polyclonal rabbit), and anti-Mouse IgG HRP antibodies were all from 125 
Santa Cruz Biotechnologies (USA). Anti-Bordetella serum (rabbit polyclonal) was a 126 
generous gift from Dr. Branislav Vecerek. Cy-3 conjugated anti-rabbit antibody was 127 
obtained from Sigma-Aldrich, USA. Rabbit polyclonal anti-cAMP antibody for 128 
competitive ELISA was obtained from Genscript, USA. Transwell permeable filter 129 
supports (0.4 µm pore size, Polyester membrane) were bought from Corning Costar 130 
Corporation, USA. F-actin staining was done with Alexa Fluor 488 phalloidin (Molecular 131 
Probes, Thermo Scientific, USA). Anti-human ZO-1 antibody was also obtained from BD 132 
biosciences. Radio-Immunoprecipitation Assay (RIPA) buffer was purchased from 133 
Sigma Aldrich, USA; and used along with protease inhibitor cocktail and phosphatase 134 
inhibitors obtained from Life Technologies, USA. Micro BCA Protein Assay kit for protein 135 
estimation was obtained from Thermo Fisher Scientific, USA. Recombinant human IL-136 
17A and human beta defensin-2 (hBD-2) standard TMB ELISA development kit were 137 
obtained from Peprotech, UK. Human CXCL8/IL-8 and human IL-6 ELISA kits were 138 
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purchased from R&D systems, UK. FITC Annexin V Apoptosis Detection Kit I was 139 
obtained from BD Biosciences, USA. Human MUC5AC ELISA kit was obtained from 140 
LifeSpan BioSciences, Inc; USA. Mouse monoclonal anti-CyaA antibody (9D4) was 141 
kindly provided by Erik L. Hewlett (University of Virginia School of Medicine, 142 
Charlottesville, USA). A mouse poly-clonal serum recognizing the S1 subunit of 143 
pertussis toxin was a kind gift of Nicole Guiso, Institut Pasteur, Paris, France and a mAb 144 
recognizing the N-terminal region of filamentous hemagglutinin was a kind gift of 145 
Camille Locht, Institut Pasteur Lille, France. Pertactin polyclonal rabbit serum was 146 
generated in SPF rabbits by immunization with recombinant purified P69 form of 147 
pertactin. 148 
Production and purification of CyaA. CyaA and the CyaA-AC- toxoid (with AC 149 
enzyme activity ablated by a GlySer dipeptide insert between residues 188 and 189) 150 
were produced in the E. coli strain XL1-Blue (Stratagene, La Jolla, CA). The proteins 151 
were purified by a combination of ion exchange chromatography on DEAE-Sepharose 152 
and hydrophobic chromatography on Phenyl-Sepharose, as described in detail 153 
elsewhere (20, 39) and were stored in 50 mM Tris pH 8.0, 8 M urea, and 2 mM CaCl2 154 
(TUC buffer) at -20 °C.  155 
Cell Culture and Air-Liquid Interface (ALI). An E6/E7 viral oncogene 156 
immortalized human bronchial epithelial cell line VA10 was cultured as described 157 
previously (40). Briefly, the cells were maintained in B/TEGM with antibiotic-antimycotic 158 
solution (0.1 mg/ml streptomycin, 100 U/ml penicillin, and 0.25 µg/ml amphotericin) at 159 
37 °C and 5% CO2. ALI cultures were set up on transwell permeable filter supports. 160 
Cells were seeded in B/TEGM medium with antibiotic-antimycotic solution. Three to four 161 
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days after seeding, medium was changed to DMEM/F12 supplemented with 2% 162 
Ultroser G and antibiotic-antimycotic solution on both apical and basolateral sides. 163 
Three to four days later the medium was removed from the apical surface. The cells 164 
were cultured at the air–liquid interface for 21 days, with media changed every second 165 
day. Mature ALI cultures (VA10 cell layers) that generated transepithelial resistance 166 
(TEER) of at least 350 Ω.cm2 were used for further studies.  167 
Bacterial strains and co-culture experiments. The Bordetella pertussis 168 
Tohama I (WT) isolate was obtained as the CIP 81.32 strain from the Collection of 169 
Institute Pasteur, Paris, France. The B. pertussis ΔcyaA mutant, carrying an in-frame 170 
deletion of the cyaA open reading frame on the chromosome (ΔcyaA) was constructed 171 
using the pSS4245 allelic exchange vector (generously provided by Dr. S. Stibitz), as 172 
described in detail elsewhere (19). B. pertussis strains were grown on BGA plates 173 
(Bordet-Gengou agar, Becton Dickinson) containing 15% defibrinated sheep blood. 174 
Colonies from a fresh plate were resuspended to OD600 = 0.2 in modified Stainer-175 
Scholte medium (supplemented with 1g/l of casamino acids and 1 g/l 2-hydroxypropyl-176 
β-cyclodextrin). The bacteria were grown overnight at 37 °C with shaking to OD600 = 1 177 
(2 x 109 colony forming units (CFU)/ml). Bacterial suspensions were diluted in 178 
DMEM/F12 with 10% FCS and no antibiotics to ~2 x 107 CFU/ml and incubated further 179 
at 37 °C for 1 hour before addition to the apical side of VA10 cell layers at a multiplicity 180 
of infection (MOI) of 50 (unless stated otherwise). It was controlled by Western blotting 181 
that there was no observable difference in the production of FHA, PTX, and pertactin 182 
between the WT B. pertussis and the CyaA-deficient B. pertussis ΔcyaA strains (Fig. 183 
S1).  184 
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Trans-epithelial electrical resistance (TEER). TEER was measured with a 185 
Millicell-ERS volt-ohm meter (Millipore, USA). For experiments with B. pertussis, the 186 
bacteria in DMEM/F12 with 10% FCS and no antibiotics were added to the apical side 187 
of VA10 cell layers. CyaA or CyaA-AC- was diluted in DMEM/F12 with 2% UltroserG 188 
and antibiotic-antimycotic solution. Background resistance of empty transwell filters was 189 
subtracted. The TEER was calculated as Ω.cm2. 190 
In control experiments forskolin (5 µg/ml) or 100 µM di-butyryl cAMP (Santacruz 191 
Biotechnologies, USA) were dissolved in Dimethyl Sulfoxide (DMSO) according to 192 
manufacturer’s instructions. The final concentration of DMSO was kept at 0.1% v/v or 193 
less and did not affect the expression of target genes or TEER at this concentration. 194 
Adenylate cyclase assay. Adenylate cyclase (AC) activities were measured as 195 
previously described in the presence of 1µM calmodulin (41). One unit of AC activity 196 
corresponds to 1 µmol of cAMP per minute at 30 °C. For determination of CyaA 197 
penetration across the cell layer, 10 µl of the basal chamber medium was assayed at 24 198 
hours after apical B. pertussis infection.  199 
 Apoptosis assay. VA10 cell layers were treated with TUC buffer, CyaA, or 200 
CyaA-AC- as mentioned above for 24 hours at 37 °C and the cell layers were washed 201 
twice with PBS-EDTA. Cells were detached with Trypsin-EDTA for 7-10 minutes at 37 202 
°C and 10% Fetal calf serum was added. The cells were washed twice and assayed for 203 
apoptosis by the FITC Annexin V Apoptosis Detection Kit I according to manufacturer’s 204 
instructions. 205 
Immunofluorescent staining. For confocal microscopy, cells on transwell 206 
support membranes were washed twice with ice-cold PBS and fixed using cold 207 
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methanol (-20 °C) for 15 minutes, permeabilized with acetone (-20 °C) for 50 seconds 208 
and rinsed with methanol again. Sequential rehydration was carried out using 70 %, 50 209 
%, and 30 % methanol at 4 °C for 5 minutes each. After fixation, the cell layers were 210 
washed with PBS and blocked with 5 % BSA in PBS for 30 minutes at room 211 
temperature. After fixation and blocking, the membrane with cell layer was extracted 212 
from the polystyrene support using sharp forceps. The cells were probed with the 213 
primary antibody diluted in 2% BSA in PBS for 60 minutes, washed three times with 214 
PBS and stained in 2 % BSA with fluorochrome-conjugated secondary antibody along 215 
with DAPI (1 µg/ml) for 30 minutes. Finally, the cell layers were washed with PBS, 216 
rinsed once with distilled water, and mounted on a clean microscopic slide in 217 
Vectashield mounting medium (Vector laboratories). Immunofluorescent images were 218 
obtained using Olympus FV-1000 confocal microscope (Olympus Corporation, Tokyo, 219 
Japan). Tight Junction Organization Rate (TiJOR) was calculated using an ImageJ 220 
macro (42), to evaluate the damage to tight junction networks. TiJOR (entire image) 221 
was calculated by evaluating the entire representative images obtained from confocal 222 
microscopy. TiJOR for Bordetella foci was calculated by evaluating the specific areas of 223 
images where the bacteria were localized. Correspondingly, an area of untreated cell 224 
layers was arbitrarily chosen as a control to best represent the tight junction network. 225 
The starting area (60 x 60 units) and parameters (20 polygons, 4 steps) of evaluation 226 
were kept constant through all ‘Bordetella foci’ evaluations. Mucin 5AC and F-actin 227 
staining was quantified using Image J. 228 
cAMP assay. ALI-grown VA10 cell layers were treated with indicated 229 
concentrations of CyaA (0.1, 0.5, 5 µg/ml) added apically or basally for 30 minutes at 37 230 
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°C in DMEM with 10% FCS. The reaction was stopped by lysing the cells with 0.2% 231 
Tween in 50 mM HCl. cAMP levels in the lyzate were determined by a competitive 232 
ELISA as mentioned elsewhere (43, 44). cAMP concentrations were normalized to total 233 
protein content determined using a Micro BCA protein assay kit (Bio-Rad, Rockford, 234 
USA).  235 
Mucin 5AC ELISA. Intracellular mucin 5AC production was measured using the 236 
Human MUC5AC ELISA kit (LifeSpan BioSciences, Inc; USA) according to 237 
manufacturer’s instructions. Toxin treated VA10 cell layers were detached from the 238 
membrane, lysed by a sequential freeze-thaw procedure (4 times, freezing in liquid 239 
nitrogen, thawing in 37 °C water bath), centrifuged, and the supernatant was used for 240 
ELISA.  241 
Cytokines and hBD-2 measurement. IL-17A, CyaA, or both, were added in 242 
DMEM/F12 with 2% UltroserG and antibiotic-antimycotic solution to the basolateral side 243 
of VA10 cell layers. Basolateral supernatants were collected after 24 hours of 244 
incubation, and cytokine/hBD-2 levels were determined by ELISA according to 245 
manufacturer’s instruction. Concentrations were calculated from calibration curves using 246 
the MasterPlex ReaderFit software (Hitachi SolutionsAmerica, San Diego, CA, USA) by 247 
generating four parameter logistic curve-fit. 248 
RNA isolation and quantitative real time PCR. Total RNA was isolated using 249 
the NucleoSpin RNA kit (Macherey-Nagel, Germany, Cat.No. 740955) and quantified 250 
using a Nanodrop spectrophotometer (Thermo Scientific, USA). Isolated RNA was 251 
reverse transcribed into first strand cDNA using High capacity cDNA reverse 252 
transcription kit according to manufacturer’s instructions ( Life Technologies, USA). The 253 
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cDNA was quantified with Power SYBR green Universal PCR master mix (Applied 254 
Biosystems, USA) on a 7500 Real time PCR machine (Applied Biosystems, USA). 255 
Ubiquitin C (UBC) gene was used as a reference in all the quantitative real time PCR 256 
(q-RT PCR) experiments. A non-template control was included in all experiments. Some 257 
primers were designed using Primer3 or Perl primer (Table S1). All additional primers 258 
were purchased from Integrated DNA technologies (PrimeTimeTM predesigned qPCR 259 
Assays) and were used at a final concentration of 500 nM according to manufacturer’s 260 
instructions, unless stated otherwise. All primers gave a single PCR product as 261 
evaluated with the aid of a melting curve. The default cycling conditions were as 262 
followed: 1) initial denaturation; 95°C for 10 min followed by 40 cycles of: 2) 263 
denaturation step; 95°C for 15 sec and 3) annealing/extension step: 60°C for 1 min. The 264 
2(-ΔΔCT) Livak method was utilized for calculating fold difference over untreated control 265 
(45).  266 
Western blot analysis. CyaA-treated cell layers were washed three times with 267 
ice-cold PBS, incubated for 30 min on ice with complete RIPA lysis buffer. The lyzate 268 
was cleared at 12,000 rpm for 10 min at 4°C and its protein content was determined by 269 
the Bradford method (Bio-Rad, USA). The proteins were separated by SDS-PAGE (4-270 
12% gradient Bis-Tris SDS gels, Life Technologies, USA) and transferred onto a PVDF 271 
membrane (Millipore, USA) using the NuPage blotting kit (Life Technologies, USA). 272 
Upon blocking with 5% non-fat skimmed milk in 1x PBS with 0.05% Tween 20 (PBST), 273 
the membranes were probed with primary antibodies diluted 1:200-1:1000 in PBST with 274 
0.5% non-fat skimmed milk or 2% bovine serum albumin, according to recommendation 275 
of antibody manufacturers. Upon repeated washing, the detected proteins were 276 
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revealed with 1:10,000-diluted horseradish peroxidase (HRP)-linked secondary antibody 277 
(Sigma Aldrich, USA) using the Pierce ECL plus chemiluminescence substrate (Thermo 278 
Scientific, USA) and an Image Quant LAS 4000 station (GE Healthcare, USA). 279 
Statistical analysis. Normally distributed results for q-RT PCR experiments are 280 
represented as means and standard error of the means from at least three independent 281 
experiments. For comparison of differences between two groups, the unpaired 282 
Student’s t-test was used. For comparison of more than two groups, one-way ANOVA 283 
test was used. For comparison of two different categorical independent variables, two-284 
way ANOVA was used. Tukey’s test or Dunnett’s test were used for post hoc analysis. 285 
P value of less than 0.05 was considered statistically significant. All the statistical 286 
analysis was performed with the Prism 6 software (Graph Pad, USA). The axis was split 287 
in some graphs to facilitate accurate representation of the trends. 288 




 B. pertussis infection compromises tight junction integrity of differentiated 291 
epithelial cell layers. We first assessed the impact of B. pertussis infection on tight 292 
junction integrity of differentiated ALI-grown VA10 bronchial epithelial cell layers. As 293 
documented in Fig. 1A, upon bacterial infection of the apical side at an approximate 294 
multiplicity of infection (MOI) of 50:1, the trans-epithelial electrical resistance (TEER) of 295 
the pseudostratified VA10 cell layers dropped progressively over 24 hours. Compared 296 
to mock-treated cell layers, the TEER was significantly reduced already after 12 hours 297 
of infection with the wild-type B. pertussis strain that produced an active CyaA toxin. 298 
Infection with the CyaA-deficient ΔcyaA strain caused a delayed and slower drop of 299 
TEER of the VA10 layer, which was not significantly different from the spontaneous 300 
decrease of the TEER of mock-treated VA10 layers. At 24 hours after infection, the 301 
difference in the magnitude of TEER decrease provoked by the WT and the ΔcyaA 302 
strains was statistically significant. Therefore, we examined the tight junction integrity of 303 
VA10 layers after 24 hours of infection by confocal immunofluorescence microscopy. As 304 
shown in Fig. 1B, in untreated VA10 cell layers the staining for the zonula occludens 1 305 
protein (ZO-1) revealed a normal ZO-1 network that is characteristic for functional tight 306 
junctions. Upon infection by both B. pertussis WT and B. pertussis ΔcyaA bacteria, the 307 
apical ZO-1 network was disrupted and delocalized. As determined by calculation of the 308 
Tight Junction Organization Rate (TiJOR) for representative series of entire confocal 309 
images (Fig. 1C), an infection by CyaA-secreting WT bacteria caused a more 310 
pronounced ZO-1 network disruption than an infection by the ΔcyaA strain. The ZO-1 311 
network was particularly disrupted in the areas designated as Bordetella foci, where 312 
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bacteria were adhering and growing in clusters (Fig. 1D). Again, a stronger decrease of 313 
TiJOR was reproducibly observed in the foci of CyaA-secreting WT bacteria than 314 
beneath the foci of the ΔcyaA mutant. This indicated that action of the CyaA toxin was 315 
specifically involved in disruption of the barrier function of the infected VA10 epithelial 316 
cell layers.  317 
 CyaA-produced cAMP signaling disrupts the barrier function of VA10 318 
layers. In line with the previous observation of Eby et al. (2010) on T84 intestinal 319 
epithelial cells, CyaA elevated cAMP more efficiently when acting from the basolateral 320 
side than from the apical side of the polarized VA10 bronchial epithelial cells (Fig. 2A). 321 
Basal side exposure to increasing CyaA concentrations yielded up to ten-fold higher 322 
levels of cytosolic cAMP than what was generated by equal amounts of CyaA applied to 323 
the apical side. At the highest used CyaA concentration of 5 µg/mL, translocation of the 324 
toxin across the basolateral membrane resulted in up to 2489±1659 pmoles of 325 
cAMP/mg of cellular protein, as compared to 158±41 pmoles of cAMP/mg protein when 326 
equal CyaA amounts were applied apically (Fig. 2A). In line with that, treatment with 500 327 
ng/ml of CyaA from the basolateral side triggered a steady decrease of TEER of the 328 
polarized VA10 layer already within the first hour from addition (Fig. 2B). In contrast, 329 
while the AC enzyme activity of CyaA in the used medium was rather stable over 330 
prolonged incubation times (Fig. S2), a reduction in TEER could only be observed after 331 
more than five hours from addition of equal amounts of CyaA to the apical side.  332 
 The CyaA-triggered decrease of TEER was clearly due to CyaA-elicited cAMP 333 
signaling and was not due to toxin-induced cell death, since the viability of CyaA-treated 334 
VA10 cells was not affected over the incubation period (Fig. S3). Moreover, no TEER 335 
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decrease was observed upon treatment with equal concentrations of the catalytically 336 
inactive CyaA-AC- toxoid that is unable to convert ATP to cAMP (Fig. 2C). Indeed, the 337 
CyaA-elicited TEER decrease could be mimicked by treatment of the VA10 cells with 338 
Forskolin (FSK, 5 µg/mL), an activator of the cellular adenylyl cyclase enzyme isoforms, 339 
or by the cell-permeable cAMP analogue dibutyryl-cAMP (db-cAMP, 100 µM). 340 
Compared to the DMSO solvent control, these cAMP signaling-eliciting compounds 341 
provoked a 70 % or 50 % reduction of TEER (Fig. 2D).  342 
 It was important to test if upon infection of the apical surface of the polarized 343 
epithelial layer by B. pertussis the secreted CyaA could cross the pseudostratified cell 344 
layer to penetrate cells from their basal side. Therefore, we assessed the amounts of 345 
CyaA accumulating in the basal chamber medium of transwells with VA10 cell layers 346 
infected by B. pertussis from the apical side. As shown in Fig. 2E for two MOI, 347 
detectable amounts of adenylate cyclase enzyme activity (CyaA) were found in the 348 
basal chamber medium after 24 hours of infection of the apical surface and cAMP 349 
accumulated in the infected cells (Fig. 2F).   350 
 The CyaA-produced cAMP signaling did not significantly alter the expression of 351 
genes encoding the tight junction proteins, such as ZO-1 (TJP1), occludin (OCLN), and 352 
claudin-1 (CLDN1) (Fig. 3A). However, as revealed by immunodetection in whole cell 353 
lyzates (Fig. 3B), the action of CyaA provoked a progressive decrease of the detectable 354 
amounts of several tight junction marker proteins, such as occludin, ZO-1, junctional 355 
adhesion molecule A (JAMA), and claudin-1. In particular, the detected amounts of 356 
occludin and ZO-1 proteins were strongly decreased already within 1 hour after toxin 357 
addition to cell layers. The JAMA and claudin-1 protein amounts decreased noticeably 358 
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only after 24 hours of incubation with the toxin, whereas the amounts of claudin-4 and of 359 
the adherens junction marker E-cadherin were almost not affected (Fig. 3B). The CyaA-360 
produced cAMP signaling thus provoked a rapid and selective degradation of some but 361 
not all of the tight junction proteins. 362 
 In line with the drop of occludin and ZO-1 protein amounts, a clear reduction of 363 
ZO-1 network organization in CyaA-treated cell layers was observed by confocal 364 
microscopy (Fig. 3C). CyaA treatment resulted in reduced TiJOR, whereas CyaA-AC- 365 
did not affect tight junction integrity (Fig. 3D), confirming that CyaA compromised the 366 
tight junction integrity through cAMP signaling.  367 
 CyaA induces mucin production and actin reorganization in polarized VA10 368 
cells. The mucus layer plays an important role in anti-microbial innate defense 369 
mechanisms, where mucin 5AC and mucin 5B are the predominant mucin species 370 
secreted by airway epithelia. As shown in Fig. 4A, CyaA-produced cAMP signaling 371 
strongly enhanced expression of the Muc5AC and Muc5B genes, as did cAMP elevation 372 
by forskolin (Fig. S4A). As detected by mucin 5AC-specific ELISA (Fig. 4B) and 373 
confocal immunofluorescence imaging (Fig. 4C and 4D), the CyaA-treated VA10 cell 374 
layers contained increased amounts of intracellularly accumulated mucin 5AC. 375 
Moreover, in line with previous observations made on neuroblastoma, epithelial or 376 
monocytic cells exposed to CyaA (46-48), the CyaA-elicited cAMP signaling provoked 377 
reorganization of the actin cytoskeleton in polarized VA10 cells (Fig. 5A and 5B). 378 
 cAMP signaling of CyaA differentially affects production of antimicrobial 379 
peptides and cytokines. B. pertussis infection of cultured non-polarized bronchial 380 
epithelial cells was previously shown to result in a pro-inflammatory alteration of 381 
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expression profiles of NFκB-regulated genes, but the role of CyaA in these alterations 382 
was not analyzed (49). Therefore, we used qPCR to investigate the impact of CyaA 383 
toxin action on expression of genes encoding cytokines and antimicrobial 384 
peptides/proteins that are known to play an important role in innate immune functions of 385 
the epithelial layers (Fig. 6). In the examined set of genes encoding antimicrobial 386 
peptides/proteins (Fig. 6A to 6F), such as cathelicidin (CAMP), human beta defensin-1 387 
(hBD-1), human beta defensin-2 (hBD-2), lysozyme (LZY), secretory leukocyte 388 
peptidase inhibitor (SLPI) and lactoferrin (LTF), a significant downregulation of 389 
expression of the hBD2-encoding gene was observed already within 1 hour after CyaA 390 
addition to the basolateral side of the VA10 layers (Fig. 6C). In contrast, the CyaA-391 
induced changes of the mRNA levels for CAMP, hBD1, LZY, SLPI and LTF proteins 392 
was not significant (Fig. 6A, B, D, E, and F). 393 
 CyaA action resulted in a statistically significant suppression of expression of 394 
genes for the proinflammatory cytokines tumor necrosis factor-alpha (TNF-α), 395 
interleukin-1 beta (IL-1β), and interleukin 8 (IL-8). The effect was noticeable within 1 396 
hour from CyaA addition and it was most pronounced after 24 hours of toxin treatment 397 
(Fig. 6G, 6I and 6K). On the contrary, within 1 hour from toxin addition, the action of 398 
CyaA provoked some enhancement of expression of genes coding for interleukin-1 399 
alpha (IL-1α), interleukin-6 (IL-6), and interleukin-10 (IL-10). However, the expression of 400 
these genes returned to basal levels, or below them, within 24 hours from toxin addition 401 
(Fig. 6H, 6J and 6L). All these effects reflected the cAMP signaling capacity of CyaA 402 
and could be elicited by drugs elevating cAMP levels in cells, while the CyaA-AC- toxoid 403 
had no effect (Figure S4B, S4C, S4D, and S6). 404 
20 
 
 CyaA modulates IL-6, IL-8, and hBD-2 secretion in VA10 cell layers. To verify 405 
that the altered gene expression levels translated into altered levels of secreted 406 
cytokines and antimicrobial peptides, the cells were treated with 500 ng/mL of CyaA in 407 
the presence or absence of IL-17A. This cytokine was shown to activate the innate 408 
immune functions of epithelial cells (50), such as the expression of the TNF gene (TNF-409 
α, Fig. S5A), or of the DEFB4A gene (hBD-2, Fig. S5B). Indeed, CyaA action could 410 
eliminate this enhancing effect of IL-17A treatment at least in part, whereas CyaA-AC- 411 
could not (Fig. S5). 412 
 To corroborate the impact of CyaA action on production of the canonical 413 
epithelial cytokines IL-6 and IL-8 (51), and of the antimicrobial peptide hBD-2 (50), the 414 
VA10 cell layers were treated with 500 ng/mL of CyaA in the presence or absence of 415 
stimulation with 100 ng/mL of recombinant IL-17A. The levels of IL-6, IL-8, and hBD-2 416 
secreted into the basolateral supernatant of the cultures after 24 hours of treatment 417 
were then determined by ELISA. As shown in Fig. 7, CyaA treatment triggered an 418 
enhanced secretion of IL-6 even in the absence of any stimulation and the effect was 419 
potentiated in the presence of IL-17A (Fig. 7A). In contrast, CyaA action alone had no 420 
effect on the amount of secreted IL-8, while this was enhanced upon stimulation with IL-421 
17A and CyaA action interfered only marginally with the enhancing effect of IL-17A 422 
stimulation (Fig. 7B). Similarly, despite of a reduced expression of the defensin gene (cf. 423 
Fig. 6C), CyaA activity did not significantly reduce the basal amount of hBD-2 secreted 424 
from cells within 24 hours of toxin action. However, in the presence of CyaA the 425 
enhancing effect of IL-17A on secretion of hBD-2 was suppressed, showing that CyaA 426 




We used here the model of ALI-grown differentiated human bronchial epithelial 429 
VA10 cells to assess the impact of B. pertussis infection on airway epithelial layers, 430 
placing a particular emphasis on the contribution and role of CyaA in compromising of 431 
the epithelial barrier and innate immunity functions. 432 
 B. pertussis is an obligatory human pathogen with no known environmental 433 
reservoir. The mouse model of respiratory infection replicates certain aspects of human 434 
pertussis pathophysiology, but does not reproduce the full spectrum of the disease 435 
symptoms. These symptoms can be rather truly reproduced in the recently developed 436 
baboon infection model, the use of which is limited by high cost and low numbers of 437 
animals available per test group (52). The need for detailed understanding of the 438 
infection thus calls for the development of alternative in vitro models for controlled 439 
studies on molecular aspects of B. pertussis interaction with the airway epithelium.  440 
 Mammalian epithelial cells grown as submerged monolayers may lack important 441 
phenotypic and physiological features of the polarized differentiated human airway 442 
epithelial tissue. Indeed, highly differentiated primary human airway epithelial cell layers 443 
and cultured HBE-2 bronchial epithelial cells were recently be used for infection with B. 444 
pertussis to study the role of fimbriae in bacterial adherence to ciliated cells (53). We 445 
used here VA10 epithelial cells, polarized and differentiated at an air-liquid interface 446 
(ALI), which form pseudostratified epithelial layers with apicobasal polarity, functional 447 
tight junctions and TEER, the hallmarks of epithelial barrier function (40, 54). A previous 448 
study from our group showed that infection by the opportunistic pathogen Pseudomonas 449 
aeruginosa provokes complete loss of TEER, where the barrier function of ALI-grown 450 
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VA10 layers is obliterated by a coordinated action of numerous secreted cytotoxic 451 
factors (37). In contrast, B. pertussis infection produced a relatively modest reduction in 452 
TEER of the epithelial layer and this process involved the action of CyaA. Our results on 453 
polarized VA10 cells confirm the observations of Eby et al. (2010) that polarized T84 454 
cell monolayers were rather resistant to cAMP intoxication by CyaA applied to the apical 455 
side. Indeed, CyaA penetrated polarized cells more efficiently across the basolateral 456 
membrane (cf. Fig. 2A). Importantly, we have observed here that CyaA secreted by B. 457 
pertussis attached to the apical side can cross the pseudostratified epithelial layer and 458 
act on cells from their basal side. This indicates that in the course of natural Bordetellae 459 
infections the CyaA toxin action compromises the barrier function of airway epithelia. 460 
 The cell polarity effect of CyaA action on epithelial cell layers is intriguing and 461 
deserves further investigation. One of its plausible explanations could be the specific 462 
localization of phosphodiesterase 4D to the cytosolic side of the apical membrane. 463 
Indeed, phosphodiesterase 4 is regulated by the cAMP-activated protein kinase A 464 
(PKA) and forms a cAMP diffusion barrier on the apical side of airway epithelia (55). 465 
Alternatively, an unfavorable composition of the apical membrane might present a 466 
particular obstacle for efficient membrane insertion and translocation of CyaA into 467 
cytosol of epithelial cells. Delivery of the AC enzyme of CyaA into cytosol of cells was 468 
previously shown to depend on the presence of cholesterol-rich lipid microdomains 469 
through which the AC domain of membrane-inserted CyaA can accomplish the 470 
translocation across the lipid bilayer into the cytosolic compartment to catalyze 471 
formation of cAMP (15). The apparently higher efficacy of CyaA translocation through 472 
the basal membrane might then potentially be due to its lipid composition and higher 473 
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cholesterol or glycolipid content. On airway epithelial cells the expression of the 474 
proteinaceous receptor for CyaA (CD11b/CD18) has not been observed (56, 57) and in 475 
the absence of CD11b/CD18 expression the toxin might be binding to surface 476 
expressed glycosylated structures, such as the gangliosides clustered in the membrane 477 
microdomains (43, 58-60). This hypothesis would go well with the observed apicobasal 478 
polarity in the distribution of receptors on airway epithelia (61, 62). 479 
 We show here that CyaA secreted by B. pertussis bacteria adhering to the apical 480 
surface can cross the epithelial layer as the functionality of tight junctions gets 481 
compromised. It remains to be established if this is due to the sole action of the CyaA 482 
toxin. B. pertussis produces a number of other virulence factors that might affect tight 483 
junction integrity of epithelial layers. It is conceivable that pertussis toxin, tracheal 484 
cytotoxin, type III secretion effectors, or dermonecrotic toxin action may cooperate with 485 
CyaA in compromising tight junction functions. Moreover, in the context of bacterial 486 
infection, the CyaA toxin or the pertussis toxin delivered through the apical membrane 487 
by outer membrane vesicles (25, 63) might also be involved in attenuation of tight 488 
junction integrity. Such attenuation of tight junctions would open the paracellular route 489 
for the free secreted CyaA to access the basal side of the cell layer; intoxicate epithelial 490 
cells effectively and thus generate a positive feedback loop of sustained elevation of 491 
cAMP and disruption of tight junction integrity.  492 
We show here that CyaA-provoked loss of TEER is accompanied by decrease of 493 
detectable amounts of several tight junction proteins, whereas their mRNA expression 494 
levels are not significantly affected. This indicates that CyaA-provoked degradation of 495 
those proteins. Similar reduction in levels of ZO-1 and occludin has also been observed 496 
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upon treatment of Caco-2 cell layers with Staphylococcus aureus α-toxin that 497 
permeabilizes cellular membrane and enables influx of extracellular calcium ions into 498 
cells (64). Indeed, elevation of intracellular Ca2+ concentration due to ionomycin was 499 
shown to cause drop in TEER (65-67). Translocation of the AC domain polypeptide 500 
across the cell membrane is itself accompanied by calcium influx and in certain cell 501 
types the CyaA-generated cAMP can open the L-type calcium channels (68, 69). CyaA 502 
oligomerizes into pores that mediate efflux of potassium ions, as does the α-toxin. On 503 
the other hand, almost no impact on TEER and tight junction protein localization was 504 
observed in VA10 cells upon treatment with the CyaA-AC-toxoid (cf. Fig. 3), while the 505 
toxoid still causes a spike of calcium influx into cells and triggers potassium efflux from 506 
cells (68, 70, 71). Furthermore, the effects of CyaA action could largely be mimicked by 507 
cAMP elevation in cells exposed to forskolin or to db-cAMP, a cell-permeable cAMP 508 
analogue. It can thus be concluded that deregulated signaling of CyaA-produced cAMP 509 
was the dominant mechanism by which CyaA provoked loss of tight junction integrity of 510 
VA10 layers. However, this was not complete when the cells were treated with forskolin 511 
or db-cAMP. This indicates that also ATP depletion triggered by CyaA may have been 512 
involved in the disruption of tight junction integrity upon prolonged exposure of cells to 513 
CyaA. Indeed, Eby et al. (2012) have observed that 500 ng/mL of CyaA could cause 514 
ATP depletion in epithelial cells and a loss of tight junction integrity following ATP 515 
depletion was previously observed (72, 73).  516 
A further element that might be contributing to loss of TEER and barrier function 517 
of the CyaA-treated epithelial layer likely was the cAMP-induced reorganization of actin 518 
and cell shape change. CyaA activity was previously shown to promote cell shape 519 
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changes in rat alveolar epithelial cells (47). Moreover, CyaA action through transient 520 
inactivation of RhoA (48), was shown to cause massive actin cytoskeleton 521 
rearrangements and membrane ruffling in macrophages, where Rho activity was shown 522 
to be important for the maintenance of the barrier function of epithelia (74). 523 
In this respect, it is noteworthy that elevation of cellular cAMP can have 524 
contrasting effects on tight junction function, depending on the cell/tissue type. For 525 
example, cAMP at certain levels promotes localization of occludin and ZO-1 to tight 526 
junctions in Caco-2 cells (75). Further, CyaA toxin action on innate immune functions of 527 
the polarized epithelium comprised the transcriptional upregulation of mucin genes, 528 
which has also been seen upon infection with B. pertussis (49). Our results show a clear 529 
cAMP-mediated increase of amounts of the goblet cell marker mucin 5AC in VA10 cell 530 
layers. A cAMP-mediated increase in mucin secretion has been reported previously (76) 531 
and it is plausible to speculate that CyaA action could promote differentiation of p63 532 
positive basal cells (phenotype of VA10 cells) into mucin-producing goblet-like cells, as 533 
seen upon IL-13 treatment (54). Enhanced mucin production might then be supporting 534 
B. pertussis infection and transmission, as the bacteria exploit mucin as a binding 535 
substrate (49, 77) and are transmitted in mucus containing aerosol droplets (78). 536 
Another effect of CyaA action on the VA10 cell layers consists of modulation of 537 
transcription of genes encoding important cytokines and antimicrobial peptides. CyaA 538 
treatment resulted in pronounced downregulation of the DEFB4A gene coding for hBD-2 539 
already at 1 hour post CyaA treatment and the secretion of hBD-2 was reduced to basal 540 
level in the presence of CyaA even upon concomitant stimulation by IL-17A (cf. Fig. 541 
7C). Since it has been shown that B. pertussis is susceptible to bacteriostatic action of 542 
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hBD-2 (79), the suppression of hBD-2 production by CyaA may represent an important 543 
contribution to overcoming of innate immune mechanisms of the epithelia by B. 544 
pertussis.  545 
The other effects of CyaA action comprised enhanced secretion of IL-6 from 546 
epithelial cells, as observed previously (80) and decrease of IL-17A-induced secretion 547 
of IL-8. The effects on transcription of genes encoding the TNF-α, IL-10, IL-1β, or IL-1α 548 
cytokines were statistically significant but their biological relevance remains to be 549 
corroborated. Many of the above-mentioned genes are modulated by the nuclear factor 550 
kappa-B (NF-kB) (81). For example, the hBD-2 gene has three NF-kB binding sites in its 551 
promoter region (82) and NF-kB activation mediates the initial transcriptional response 552 
in epithelial cells infected by B. pertussis (49). On the other hand, cAMP signaling can 553 
selectively modulate NF-kB activity and can yield both pro-inflammatory and anti-554 
inflammatory responses that are highly tissue/gene-dependent (83). Our results show 555 
that cAMP signaling can upregulate expression of the genes encoding IL-6 and mucin 556 
5AC, known to be positively regulated by NF-kB (84, 85); whereas it downregulates the 557 
transcription of genes encoding hBD-2 and IL-1β, which are also controlled by NF-kB 558 
(82, 86). This complexity of regulation is due to modulatory effects of the cAMP/PKA-559 
activated signaling pathways on the transcriptional co-activators that are directly 560 
controlled by the cAMP response element binding protein (CREB) (87). It has been 561 
shown that PKA phosphorylated CREB can indirectly inhibit NF-kB by competing for its 562 
co-activator, the CREB-binding protein (CBP) (88). Expression of genes encoding 563 
mucin 5AC and IL-6 has been described to be dually regulated by CREB and NF-kB 564 
27 
 
(89, 90). Hence, the strength and duration of the signal and tissue/gene specificity will 565 
decide if the expression of a certain gene is upregulated or downregulated.  566 
IL-17A is an important pro-inflammatory cytokine secreted by activated T cells 567 
(Th17). It signals through the IL-17 receptor of epithelial cells and stimulates production 568 
of important cytokines, such as IL-6 and IL-8 (51), or of antimicrobial peptides, like hBD-569 
2 (50). Our results suggest that although IL-17 would be produced by the immune cells 570 
arriving to the site of B. pertussis infection, the action of CyaA may be skewing the 571 
response of epithelial cells to such IL-17 stimulation. It would potentiate IL-17A-induced 572 
IL-6 secretion (cf. Fig. 7A) but suppress the IL-17A-induced hBD-2 production. 573 
Moreover, CyaA action caused only a modest inhibition of the IL-17A-induced 574 
production of the neutrophil attracting chemokine IL-8. This must not necessarily be a 575 
problem for the infecting bacterium, as cAMP intoxication by the secreted CyaA 576 
paralyzes the bactericidal functions of neutrophils very efficiently (18).  577 
In conclusion, we present here a model of B. pertussis infection of polarized 578 
human bronchial epithelial cells forming pseudostratified layers, where specific effects 579 
on the function of bronchial epithelium could be attributed to CyaA toxin activity. This 580 
will facilitate deciphering of the molecular mechanisms of action of B. pertussis 581 
virulence factors on airway epithelia. 582 
  583 
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FIGURE LEGENDS 843 
FIG 1: B. pertussis infection compromises the tight junction integrity of VA10 844 
bronchial epithelial cell layers. (A) The apical surfaces of mature ALI-grown VA10 cell 845 
layers were infected (MOI = 50) with B. pertussis (WT) or its CyaA deficient mutant 846 
(ΔcyaA). Transepithelial electrical resistance was measured across cell layers at 847 
different time intervals. Data represents mean ± SEM (N = 5). ** p<0.01, **** p<0.0001 848 
compared to untreated; # p<0.05 compared to WT (two-way ANOVA). (B) Confocal 849 
images of VA10 cell layers treated for 24 hours as in (A), washed, fixed, and stained for 850 
ZO-1 (green), Bordetella (red) and nuclei (blue). N = 4, scale bar 10 µm. Reconstructed 851 
Z stack projections are shown below the main image. (C) Tight Junction Organization 852 
Rate (TiJOR) was calculated for representative entire images from four independent 853 
experiments using ImageJ; bars represent mean ± SEM, N = 4; * p<0.05 according to 854 
one-way ANOVA. (D) Areas, where the growth of adhering bacteria was localized, were 855 
manually selected and the TiJOR was calculated for images from four independent 856 
experiments. An area of untreated cell layers was arbitrarily chosen as a control and 857 
analyzed using the same parameters. N = 4, bars represent mean ± SEM; ** p<0.01, *** 858 
p<0.001 according to one-way ANOVA compared to untreated. Untreated cell layers 859 
were used as control.  860 
FIG 2: CyaA-mediated cAMP intoxication disrupts tight junction integrity. (A) VA10 861 
cell layers were treated with CyaA toxin in DMEM plus 10% FCS from the apical or 862 
basolateral side for 30 minutes. Cellular cAMP levels were determined and normalized 863 
to cellular protein concentration. N = 3. (B) CyaA (500 ng/ml) or TUC buffer in 864 
DMEM/F12 was added to the apical or basolateral side of VA10 cell layers and TEER 865 
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was measured at several time intervals of incubation at 37 °C and expressed as relative 866 
TEER (%), taking the starting TEER as 100%. N ≥ 3; * p<0.05, **<0.01, ****p<0.0001 867 
compared to TUC (two-way ANOVA). Cell layers were treated with CyaA or the 868 
catalytically inactive CyaA-AC- toxoid (C); 5 µg/ml of forskolin (FSK) or 100 µM 869 
dibutyryl-cAMP (db-cAMP) (D); from the basolateral side and TEER was measured at 870 
time 0 and 24 hours. The shown values represent mean ± SEM, N = 3. * p<0.05, ** 871 
p<0.01 compared to control (Student’s t-test). (E) VA10 cell layers were apically infected 872 
with B. pertussis WT at different MOIs and after 24 hours the amount of adenylate 873 
cyclase toxin that reached the basal chamber medium was determined. Bars represent 874 
mean ± SEM, N = 4, ** p<0.01 compared to MOI = 0 (one-way ANOVA). The basal 875 
medium was free of any culturable bacteria, as verified by plating 100 µl of the medium 876 
on BGA plates. (F) VA10 cell layers were infected as in (E) and the cellular cAMP levels 877 
were determined. Bars represent mean ± SEM, N = 4, * p<0.05, ** p<0.01 compared 878 
MOI = 0 (one-way ANOVA).     879 
FIG 3: CyaA-produced cAMP signaling causes disruption of tight junction 880 
complexes. (A) VA10 cell layers were treated from the basolateral side with 500 ng/ml 881 
of CyaA for 1, 6, and 24 hours at 37 °C and the levels of mRNA for tight junction 882 
proteins were assayed by q-RT PCR; UBC was used as a reference gene. Bars 883 
represent the mean ± SEM, N = 3. (B) Cell layers were treated as described in (A), 884 
lysed, and probed by immunoblotting with antibodies recognizing the tight junction 885 
complex proteins. GAPDH was used as a loading control and the blots are 886 
representative of two independent experiments. (C) Cell layers were treated 500 ng/ml 887 
of CyaA, CyaA-AC-, or TUC buffer from the basolateral side for 24 hours at 37 °C. 888 
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Confocal images of fixed cell layers were stained for the tight junction protein ZO-1 889 
(green). The scale bar is 100 µm. Tight Junction Organizational Network rate (TiJOR) 890 
for the entire image was calculated for ZO-1 (B). Bars represent mean ± SEM of three 891 
experiments; * p<0.05 compared to TUC (one-way ANOVA). 892 
Fig 4: CyaA enhances mucin production in epithelial cell layers. (A) 500 ng/ml 893 
CyaA, 1000 ng/ml CyaA-AC-, or TUC buffer in DMEM/F12 was added to the basolateral 894 
side of VA10 cell layers for 3 or 24 hours at 37 °C. Relative expression of genes 895 
encoding mucin 5AC and mucin 5B were analyzed by q-RT PCR. Bars represent mean 896 
± SEM of three experiments. *** p<0.001, **** p<0.0001 compared to TUC (one-way 897 
ANOVA). (B) Cell layers were treated with 500 ng/ml of CyaA, CyaA-AC-, or TUC buffer 898 
for 24 hours as mentioned in (A) and the amounts of intracellularly accumulated mucin 899 
5AC were measured by ELISA. Bars represent mean ± SEM of three experiments. * 900 
p<0.05 compared to TUC (students t-test). (C) Cell layers were treated as in (B), fixed, 901 
stained for the goblet cell marker mucin 5AC (red) and imaged by confocal microscopy. 902 
Scale bar is 100 µm. (D) Mean fluorescence intensity (± SEM) of mucin 5AC staining; N 903 
= 3, ** p<0.01 compared to TUC (one-way ANOVA).    904 
FIG 5: CyaA disrupts actin cytoskeleton in epithelial cell layers. (A) Cell layers 905 
were treated as in Fig. 4C, fixed with paraformaldehyde and stained for F-actin with 906 
Alexa Fluor 488-phalloidin (green). Scale bar is 100 µm. (B) Mean fluorescence 907 
intensity (± SEM) of F-actin staining; N = 3, p<0.05 compared to TUC (one-way 908 
ANOVA). 909 
FIG 6: CyaA modulates expression of genes encoding antimicrobial peptides and 910 
cytokines/chemokines. VA10 cell layers were treated from the basolateral side with 911 
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CyaA (500 ng/ml) in DMEM/F12 for 1, 6, and 24 hours; or TUC buffer. (A-L) Relative 912 
expression of genes encoding the antimicrobial peptides/proteins (A) Cathelicidin, (B) 913 
human beta defensin 1, (C) human beta defensin 2, (D) lysozyme, (E) secretory 914 
leukocyte peptidase inhibitor, (F) lactoferrin; and for the cytokines/chemokines (G) 915 
tumor necrosis factor-α, (H) interleukin-1α, (I) interleukin-1β, (J) interleukin-6, (K) 916 
interleukin-8, and (L) interleukin-10, were analyzed by q-RT PCR. UBC was used as a 917 
reference gene. Bars represent mean ± SEM, N = 3; ns indicates non-significant; *, p< 918 
0.05; **, p<0.01; ***, p<0.001, ****, p<0.0001 compared to TUC control (one-way 919 
ANOVA). 920 
FIG 7: CyaA enhances secretion of IL-6, while inhibiting secretion of IL-8 and 921 
hBD-2 upon stiµlation by IL-17A. VA10 cell layers were treated from the basolateral 922 
side with IL-17A (100ng/ml), CyaA (500 ng/ml), or both for 24 hours. IL-6 (A), IL-8 (B), 923 
and hBD-2(C) secretion levels were assayed from the basolateral supernatant by 924 
ELISA. Bars represent mean ± SEM of three replicates from a single experiment 925 
representative of 3 independent experiments. 926 
 927 
 928 
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